On the ropes, Infinity gets a deal for duvelisib, with $0 up front as PI3k flounders
So this is where PI3k cancer drugs have fallen to.
Infinity Pharmaceuticals, which once touted its lead drug duvelisib as a blockbuster contender, has now handed it over to the long suffering Verastem $VSTM for no money down and milestones that tap out at $28 million.
The deal leaves Infinity $INFI on the ropes, with nothing but an early-stage PI3k followup called IPI-549 in the pipeline and a long lineup of clinical pileups in its past.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.